| Prev Close | 192.99 |
| Open | 193.01 |
| Day Low/High | 191.64 / 193.38 |
| 52 Wk Low/High | 114.27 / 202.22 |
| Volume | 12.44M |
Allergan plc (AGN)
193.02
0.03
0.02
NYSE
| Exchange | NYSE |
| Div & Yield | N.A. (N.A) |
Latest News
Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession
What's really driving the market, what's making the Nasdaq roar? Tech and science, that's what.
Buffett's Great Airline Escape, Tech Leadership, ECB Wiggle Room
Don't just follow the herd, time your exits and entrances well -- even if it is a big player like Warren Buffett that is leading the charge.
Jim Cramer: I Don't Think Covid-19 Is Invincible
When it's beaten you will wish you own stocks, especially the stocks that are right now lethal to your portfolio.
Jim Cramer: Finding Any Stocks With No Hair?
After a company reports we all know what's wrong, it's immunized. And that's when you can buy.
Jim Cramer: Panicking Never Made Anyone a Dime, but These Will
Here are six companies that should come through in the tough times ahead.
Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff
Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.
Jim Cramer: Rate Cut No Cure for Coronavirus
But don't throw up your arms yet -- here are names that could be golden opportunities.
Coronavirus Spreads, Reducing 'Big Oil', 4 Stocks to Watch, Adding Store Capital
Newly confirmed cases of the Covid-19 virus spiked from Hubei Province in China, where the city of Wuhan is located. The number of related deaths increased as well.
Threats to the Marketplace, Dollar Demand, Upcoming Alibaba Earnings
China-based Alibaba reports quarterly performance Thursday morning. While one might think that an e-commerce type operation could do well in a quarantined environment, it's not quite that easy.
Decisions, Decisions: AbbVie or Bristol-Myers Squibb?
AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.
A Technical Strategy for AbbVie as the Broader Market Gets Rocked
ABBV could bounce today but there remains the risk of a deeper correction.
Jim Cramer: 6 Stocks to Buy on Coronavirus Fears
These companies all could be strong -- even if the 2019 nCoV fear spreads.
Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average
Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.
This Dividend Aristocrat Is Our Top Pick for 2020
As it smooths out the wrinkles from 2019, this pharmaceutical manufacturer should have a healthy year.
Individual Investors Are Back! Trading Cisco: Market Recon
It seemed to happen overnight. People watched. People listened. People cared. About what? Individual stocks.
Cash Stashes Dwindle as Markets Crest and Powell Speaks: Market Recon
Plus, we preview Wednesday's Trump-Erdogan meeting and check out AbbVie's huge debt offering as well as the new Abode-Microsoft connection.
The Price of Fair Trade, Defense Stocks Volatility, Eyes on InMode: Market Recon
Investors must understand that the narrative around trade with China has evolved as the two sides work on a 'Phase One' mini-trade deal, but this is about much more than that.
Jim Cramer: Drug Stocks Are Too Cheap
These stocks are priced for total imperfection. That's just what you want.
6 Top Biopharmaceutical Stock Picks You Should Know About
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
The Long Decline in AbbVie Is Over
In addition to the yield let's check out the charts of ABBV.
Jim Cramer: Where Can You Still Get Some Growth and a Big Yield?
Right now, AbbVie is the best way to capitalize on the moment and on the future.
My Outlook for the Market's Major Sectors
* Only three of eleven S&P sectors are viewed as attractive * I am in a risk off state of mind. Back in 2015 I instituted a new regular feature called "Sectors," in which I periodically offered my short-term (6-12 months) price outlook for each of t...
These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Evolus Could See Breakout Soon
EOLS appears to have formed a small triangle pattern the past few weeks and a breakout is likely before reaching the apex.
AbbVie: The Right Mixture for the Perfect Stock
ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.
Real Money Post-Industrial Average Leads Major Indexes So Far for Year
In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.
